Evolus, Inc. (NASDAQ:EOLS) Insider Rui Avelar Sells 27,904 Shares

Evolus, Inc. (NASDAQ:EOLS) insider Rui Avelar sold 27,904 shares of Evolus stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $370,007.04. Following the completion of the transaction, the insider now directly owns 362,467 shares in the company, valued at approximately $4,806,312.42. This trade represents a 7.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Rui Avelar also recently made the following trade(s):

• On Monday, December 23rd, Rui Avelar sold 2,252 shares of Evolus stock. The shares were sold at an average price of $10.85, for a total transaction of $24,434.20.

Evolus Price Performance

NASDAQ EOLS opened at $13.25 on Friday. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The stock has a market capitalization of $842.53 million, a PE ratio of -14.56 and a beta of 1.28. The company has a 50 day moving average price of $13.36 and a two-hundred day moving average price of $13.91. Evolus, Inc. has a 12-month low of $9.25 and a 12-month high of $17.82.

Institutional Trading of Evolus

Institutional investors have recently added to or reduced their stakes in the business. KBC Group NV acquired a new stake in Evolus in the fourth quarter valued at approximately $49,000. IFP Advisors Inc lifted its stake in Evolus by 17,440.7% in the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after acquiring an additional 4,709 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Evolus in the third quarter valued at approximately $132,000. KLP Kapitalforvaltning AS acquired a new stake in Evolus in the fourth quarter valued at approximately $106,000. Finally, Rafferty Asset Management LLC acquired a new stake in shares of Evolus in the fourth quarter worth $115,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

EOLS has been the topic of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Wednesday, March 5th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Evolus in a research report on Wednesday, March 5th. Finally, Barclays boosted their price objective on shares of Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.